| Name | Title | Contact Details |
|---|
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Bravo Health, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Bravo Health, Inc. is based in Baltimore, MD. You can find more information on Bravo Health, Inc. at www.bravohealth.com
Canadian Aboriginal AIDS Network is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Geonetric is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ōmcare is a digital health company that aims to change the way the world cares by extending the reach of caregivers, increasing medication adherence, and improving treatment outcomes through the power of remote care and two-way video technology. By partnering with pharmacies, payers, providers, and family caregivers, Ōmcare strives to help people live healthier, more vibrant, independent lives and reduce healthcare cost. Ōmcare`s first product is called the Ōmcare Home Health Hub - a web-enabled platform that dispenses medication and provides two-way, audiovisual confirmation of medication adherence while facilitating social interaction and remote telehealth care. Ōmcare exists due to the rapidly aging population; high rate of medication nonadherence; a shortage of family and professional caregivers; continued increase in health care costs; consumer preference for in-home care and aging in place; changing reimbursement for home care services; and advancements remote monitoring and wearable technology.